WO2004065569A3 - Anticorps multifonctionnels - Google Patents

Anticorps multifonctionnels Download PDF

Info

Publication number
WO2004065569A3
WO2004065569A3 PCT/US2004/001808 US2004001808W WO2004065569A3 WO 2004065569 A3 WO2004065569 A3 WO 2004065569A3 US 2004001808 W US2004001808 W US 2004001808W WO 2004065569 A3 WO2004065569 A3 WO 2004065569A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
functional antibodies
present
antigen recognition
reactive site
Prior art date
Application number
PCT/US2004/001808
Other languages
English (en)
Other versions
WO2004065569A2 (fr
Inventor
Claude Meares
Todd Corneillie
Original Assignee
Univ California
Claude Meares
Todd Corneillie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/350,555 external-priority patent/US7528235B2/en
Priority claimed from US10/625,047 external-priority patent/US7820787B2/en
Priority claimed from US10/631,258 external-priority patent/US20050026263A1/en
Application filed by Univ California, Claude Meares, Todd Corneillie filed Critical Univ California
Publication of WO2004065569A2 publication Critical patent/WO2004065569A2/fr
Publication of WO2004065569A3 publication Critical patent/WO2004065569A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

La présente invention concerne des anticorps comprenant un domaine de reconnaissance d'antigène qui se lient spécifiquement à un chelate métallique. Des anticorps mutant comprenant un site réactif non présent dans le type sauvage de cet anticorps, le site réactif étant dans une position proche du domaine de reconnaissance d'antigène ou à l'intérieur de celui-ci. Cette invention concerne aussi des procédés d'utilisation de ces anticorps pour diagnostiquer ou traiter une maladie.
PCT/US2004/001808 2003-01-23 2004-01-23 Anticorps multifonctionnels WO2004065569A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/350,555 US7528235B2 (en) 2003-01-23 2003-01-23 Multi-functional antibodies
US10/350,555 2003-01-23
US10/625,047 US7820787B2 (en) 2003-01-23 2003-07-22 Multi-functional antibodies
US10/625,047 2003-07-22
US10/631,258 2003-07-31
US10/631,258 US20050026263A1 (en) 2003-07-31 2003-07-31 Multi-functional antibodies

Publications (2)

Publication Number Publication Date
WO2004065569A2 WO2004065569A2 (fr) 2004-08-05
WO2004065569A3 true WO2004065569A3 (fr) 2005-03-24

Family

ID=32776952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001808 WO2004065569A2 (fr) 2003-01-23 2004-01-23 Anticorps multifonctionnels

Country Status (1)

Country Link
WO (1) WO2004065569A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2577815A1 (fr) * 2004-08-20 2006-03-30 The Regents Of The University Of California Fragment d'anticorps genetiquement modifie qui se lie a un antigene de maniere irreversible
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
WO2007131242A2 (fr) * 2006-05-05 2007-11-15 The Regents Of The University Of California Systeme anticorps-haptene a liaison streptavidine-biotine
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
KR20160017126A (ko) * 2007-06-12 2016-02-15 에이씨 이뮨 에스.에이. 모노클로널 항 베타 아밀로이드 항체
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
CN104411725B (zh) 2012-07-04 2018-09-28 弗·哈夫曼-拉罗切有限公司 抗生物素抗体及使用方法
CN104428006B (zh) * 2012-07-04 2017-09-08 弗·哈夫曼-拉罗切有限公司 共价连接的抗原‑抗体缀合物
EP3138578B1 (fr) 2012-07-04 2022-01-12 F. Hoffmann-La Roche AG Anticorps anti-théophylline et procédés d'utilisation
US10561737B2 (en) * 2014-01-03 2020-02-18 Hoffmann-La Roche Inc. Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
WO2015101587A1 (fr) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Conjugués hélicar-anticorps anti-hélicar liés de façon covalente et utilisations associées
CA2930046A1 (fr) * 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Conjugues toxine polypeptidique-anticorps a laison covalente
BR112016029935A2 (pt) 2014-06-26 2017-10-31 Hoffmann La Roche ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958374A (en) * 1994-03-28 1999-09-28 The Regents Of The University Of California Method for preparing radionuclide-labeled chelating agent-ligand complexes
WO2001022922A2 (fr) * 1999-09-27 2001-04-05 The Regents Of The University Of California Manipulations d'anticorps a liaison irreversible
US20030124057A1 (en) * 2001-11-28 2003-07-03 Immunomedics, Inc. Anti-DOTA antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958374A (en) * 1994-03-28 1999-09-28 The Regents Of The University Of California Method for preparing radionuclide-labeled chelating agent-ligand complexes
WO2001022922A2 (fr) * 1999-09-27 2001-04-05 The Regents Of The University Of California Manipulations d'anticorps a liaison irreversible
US20030124057A1 (en) * 2001-11-28 2003-07-03 Immunomedics, Inc. Anti-DOTA antibody

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHMURA ET AL.: "Antibodies with infinite affinity", PNAS, vol. 98, no. 15, 17 July 2001 (2001-07-17), pages 8480 - 8484, XP002984342 *
CORNEILLIE ET AL.: "Converting weak binders into infinite binders", BIOCONJUGATE CHEM., vol. 15, 2004, pages 1389 - 1391, XP002984341 *
CORNEILLIE ET AL.: "Crystal structures of two complexes of the rare-earth-DOTA-binding antibody 2D12.5: ligand generality from a chiral system", J. AM. CHEM. SOC., vol. 125, 2003, pages 15039 - 15048, XP002984343 *
CORNEILLIE ET AL.: "Irreversible engineering of the multielement-binding antibody 2D12.5 and its complementary ligands", BIOCONJUGATE CHEM., vol. 15, 2004, pages 1392 - 1402, XP002984344 *
GOODWIN ET AL.: "Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouese adenocarcinoma: a model for 90Y radioimmunotherapy", CANCER RES., vol. 54, no. 22, 15 November 1994 (1994-11-15), pages 5937 - 5946, XP000199874 *
LUBIC ET AL.: "Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma", J. NUCL. MED., vol. 42, no. 4, April 2001 (2001-04-01), pages 670 - 678, XP002984340 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
WO2004065569A2 (fr) 2004-08-05

Similar Documents

Publication Publication Date Title
WO2004065569A3 (fr) Anticorps multifonctionnels
WO2003074679A3 (fr) Optimisation d'anticorps
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
NZ599683A (en) Anti-ilt7 antibody
WO2007022520A3 (fr) Renfort induit par anticorps de reponse immune
WO2007131242A3 (fr) Systeme anticorps-haptene a liaison streptavidine-biotine
WO2002016401A3 (fr) Anticorps monoclonal ds6 et ses procedes d'utilisation
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
EP1139101A3 (fr) Immunoessai pour la protéine C-réactive
WO2003060080A3 (fr) Domaines variable d'immunoglobuline canine, anticorps caninises, et procede de production et d'utilisation associes
NZ607711A (en) Antibodies directed to her-3 and uses thereof
WO2004001381A8 (fr) Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible
WO2006102200A3 (fr) Immunodosage du docetaxel
WO2004022717A3 (fr) Variants tres faiblement immunogenes de l'anticorps humanise col-1 contre l'antigene carcino-embryonnaire
WO2006086208A3 (fr) Dosage immunologique de 5-fluoro-uracil
EP3300739A3 (fr) Anticorps et molécules correspondantes se liant aux protéines 161p2f10b
WO2006015098A3 (fr) Immunodosage du taxol
WO2005026209A3 (fr) Anticorps monoclonaux diriges contre hmgb1
TR200202799T3 (tr) AB peptidini sekanslayan insanlaştırılmış antikorlar
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2005010048A3 (fr) Anticorps de rg1 et utilisation de ceux-ci
WO2003032814A3 (fr) Anticorps se liant a un antigene cd46 associe au cancer et methodes d'utilisation associees
WO2003048302A3 (fr) Identification de cibles ou d'agents antitumoraux par immunisation et proteomique des radeaux lipidiques
AU2002327704A1 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase